Want to see JSPR full AI Analyst Report?
JSPR Stock Chart & Stats
$1.02
-$10.02(-56.58%)
At close: 4:00 PM EST
$1.02
-$10.02(-56.58%)
Day’s Range― - ―
52-Week Range$0.32 - $3.65
Previous CloseN/A
Volume4.28M
Average Volume (3M)399.98K
Market Cap
$16.28M
Enterprise Value-$5.73M
Total Cash (Recent Filing)$14.14M
Total Debt (Recent Filing)$757.00K
Price to Earnings (P/E)―
Beta2.92
Next Earnings
Aug 07, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.40
Shares Outstanding28,009,802
10 Day Avg. Volume455,991
30 Day Avg. Volume399,984
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.45
Enterprise Value/Market Cap-0.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit272.64
Enterprise Value/Ebitda0.10
Forecast
1Y Price Target
$3.00Price Target Upside194.12% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-1.1
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Clinical PipelineJasper's concentrated pipeline targeting mast cell–driven diseases with an anti-KIT antibody is a durable strategic asset. A focused, mechanism-driven program across multiple indications supports clearer development milestones, potential for targeted partnerships, and value creation if clinical data validates the approach.
Low Absolute LeverageVery low absolute debt reduces near-term solvency risk and limits interest burden, giving the company more optionality during a financing-constrained period. For a pre-revenue biotech, limited leverage preserves flexibility for strategic transactions or orderly restructuring without forced creditor pressure.
Governance And Financial Oversight StrengthenedReinforcing the audit committee signals a commitment to stronger financial governance and compliance. For a small, cash-constrained biotech it improves the credibility of reporting, supports diligence in strategic alternatives, and reduces execution risk on financings or transactions.
Bears Say
High Cash Burn / Negative Cash FlowSustained negative operating and free cash flow at this scale is structurally important: it necessitates external financing or asset transactions to continue operations, elevates dilution risk for shareholders, and constrains long-term R&D runway absent material cost cuts or capital infusions.
Pre-Revenue Loss ProfileOperating without revenue leaves the company dependent on financing or partnerships to fund development. Persistent, sizeable losses reduce equity cushion, increase financing frequency and negotiation leverage of counterparties, and create structural uncertainty around sustainable operations.
Nasdaq Compliance & Strategic Review RiskNasdaq non-compliance notice coupled with a board-led strategic alternatives review materially raises structural execution risk. Potential remedies (reverse split, asset sales, wind-down) can alter capital structure and operations, increase dilution or reduce standalone upside for long-term investors.
Jasper Therapeutics News
JSPR FAQ
What was Jasper Therapeutics’s price range in the past 12 months?
Jasper Therapeutics lowest stock price was $0.32 and its highest was $3.65 in the past 12 months.
What is Jasper Therapeutics’s market cap?
Jasper Therapeutics’s market cap is $16.28M.
When is Jasper Therapeutics’s upcoming earnings report date?
Jasper Therapeutics’s upcoming earnings report date is Aug 07, 2026 which is in 26 days.
How were Jasper Therapeutics’s earnings last quarter?
Jasper Therapeutics released its earnings results on May 14, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.486 by $0.446.
Is Jasper Therapeutics overvalued?
According to Wall Street analysts Jasper Therapeutics’s price is currently Undervalued.
Does Jasper Therapeutics pay dividends?
Jasper Therapeutics does not currently pay dividends.
What is Jasper Therapeutics’s EPS estimate?
Jasper Therapeutics’s EPS estimate is -0.28.
How many shares outstanding does Jasper Therapeutics have?
Jasper Therapeutics has 28,009,802 shares outstanding.
What happened to Jasper Therapeutics’s price movement after its last earnings report?
Jasper Therapeutics reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.486. Following the earnings report the stock price went down -11.366%.
Which hedge fund is a major shareholder of Jasper Therapeutics?
Currently, no hedge funds are holding shares in JSPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jasper Therapeutics
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
JSPR Stock 12 Month Forecast
Average Price Target
$3.00
▲(194.12% Upside)
Technical Analysis
Ownership Overview
1.15% Insiders
5.12% Mutual Funds
33.45% Other Institutional Investors
56.19% Public Companies and
Individual Investors